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Abstract 
Review on MIR373, with data on DNA/RNA and 
where the gene is implicated. 
Identity 
Other names: MIRN373, hsa-mir-373, miRNA373 
HGNC (Hugo): MIR373 
Location: 19q13.42 
Local order: Based on UCSC genome browser, 
genes flanking MIR373 oriented from centromere 
to telomere on 19q13.42 are:  
- DPRX: divergent-paired related homeobox, 
19q13.42,  
- C19MC: microRNA cluster, 19q13.42,  
- MIR371A: microRNA-371a, 19q13.42,  
- MIR371B: microRNA-371b, 19q13.42,  
- MIR372: microRNA-372, 19q13.42,  
- MIR373: microRNA 373, 19q13.42,  
- NLRP12: NLR family, pyrin domain containing 
12, 19q13.42, 
- MYADM: myeloid-associated differentiation 
marker, 19q13.42. 
DNA/RNA 
Description 
miR-373 belongs to a cluster of four microRNAs 
located on chromosome 19q13.  
The cluster is located approximately 20 kb 
downstream of the largest known cluster of 
miRNAs in the human genome, C19MC. miR-373 
belongs to a family of miRNAs; (miR-
302abcd/372/373/520be/520acd-3p) which are 
predicted to target the same genes due to the 
similarity in seed sequence (2-7 nucleotide, 
miRBASE v12.0). 
Transcription 
hsa-mir-373 (precursor miRNA) 
Accession: MIMAT0000725 
Length: 68 bp 
Sequence: 
5'-
GGGAUACUCAAAAUGGGGGCGCUUUCCUU
UUGUCUGUACUGGGAAGUGCUUCGAUUUU
GGGGUGUCCC-3' 
 
 
The miR-371-373 cluster maps in the chromosomal region 19q13.42. However, miR-371ab and miR-372/373 differ in their 
seed sequences and as such display separate functions based on their target genes. 
hsa-miR-373 (mature miRNA) Accession: MIMAT0000726 
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Length: 23 bp 
Sequence:  
5'-GAAGUGCUUCGAUUUUGGGGUGU-3' 
The miR-373 cluster was first described to be 
specifically expressed in embryonic stem cells and 
transcribed as a polycistronic transcript (Suh et al., 
2004).  
The neighbouring C19MC cluster is thought to 
have originated from the miR-373 cluster (Zhang et 
al., 2008). miR-373 has been described to be 
epigenetically regulated by DNA methylation in 
colon cancer (Tanaka et al., 2011) and in a rare 
cancer type, hilar cholangiocarcinoma (Chen et al., 
2012).  
Chromosomal alterations have been also linked to 
aberrant expression of miR-371-373 cluster. 
Indeed, 19q13.4 translocation in thyroid adenomas 
has been shown to activate both, C19MC and miR-
371-373 clusters which are in close proximity to the 
chromosomal breakpoint cluster (Rippe et al., 
2010). miR-371-373 cluster has also been reported 
to be transcriptionally regulated by WNT-signaling 
through β-catenin/LEF1 transactivation of the miR-
371-373 promoter in both, breast (MCF-7) and 
colon (HCT-116) cancer cells (Zhou et al., 2012). 
Furthermore, miRNA microarray analysis revealed 
miR-373 to be upregulated under hypoxic 
conditions in a HIF-1α-dependent manner, in both 
HeLa and MCF-7 cancer cell lines that were 
exposed to hypoxia (0,01% O2) (Crosby et al., 
2009). 
Pseudogene 
No reported pseudogenes. 
Protein 
Note 
microRNAs are not translated into amino acids. 
Mutations 
Note 
Gene mutations have not been described. 
Implicated in 
Breast cancer 
Oncogenesis 
In a miRNA genetic screen to identify regulators of 
cancer cell migration, Huang and colleagues 
(Huang et al., 2008) used a miRNA library 
consisting of 450 retro-viral miRNA vectors to 
transduce the non-invasive and non-metastatic 
estrogen-dependent breast cancer cell line MCF-7, 
which was then subjected to trans-well migration 
(Huang et al., 2008). Subsequent analysis of the 
migrated cancer cell population by miR-array 
(Voorhoeve et al., 2006) revealed that several 
members of the miR-373 family were enriched in 
the migrating cells compared with their abundance 
in the total cell population (Huang et al., 2008). The 
authors further demonstrated a pro-metastatic role 
of miR-373 and miR-520c in vivo, using xenograft 
mouse models for pulmonary metastasis, which 
mechanistically could be explained by direct 
targeting of the hyaluronan receptor CD44 (Huang 
et al., 2008). In agreement with these findings, 
qRT-PCR analysis of 11 paired primary breast 
tumors and lymph-node metastases (LN) revealed 
that miR-373 expression was upregulated in 
metastases compared to primary tumors (Huang et 
al., 2008). Similarly, the average miR-373 
expression was upregulated in 34 primary breast 
tumors of patients who were positive for LN 
compared to 38 LN negative primary tumors 
(Huang et al., 2008). In another study, using a 
SILAC-based quantitative proteomics approach, 
Yan and colleagues identified 30 genes involved in 
cancer invasion and metastasis to be downregulated 
at the protein level by miR-373 in MCF-7 cells, 
while the tumor suppressors TXNIP and RABEP1 
were validated as direct targets (Yan et al., 2011).  
However, the role of the miR-373 family in cancer 
development and progression may be cancer type 
and/or context-dependent. Keklikoglou and 
colleagues analyzed a panel of 76 primary breast 
tumors with known LN and estrogen receptor (ER) 
status for miR-373 and miR-520c expression by 
qRT-PCR. Interestingly, miR-520c was found to be 
downregulated in tumors of patients with LN 
metastasis compared to tumors of patients without, 
specifically in ER negative tumors (Keklikoglou et 
al., 2012). However, this effect was restricted in ER 
negative tumors as no significant difference in miR-
520c expression was observed between the LN 
positive and LN negative groups in ER positive 
patients (Keklikoglou et al., 2012). It is noteworthy, 
that miR-373 expression analysis was not feasible 
due to the low detection levels in both ER positive 
and ER negative patients (Keklikoglou et al., 2012). 
In the same study, several members of miR-373 
family were shown to downregulate the secretion of 
pro-inflammatory and pro-angiogenic cytokines by 
mammary epithelial and cancer cells, while cancer 
cell invasion and intravasation of the highly 
invasive and ER negative breast cancer cell line, 
MDA-MB-231, was inhibited both in vitro and in 
vivo, by targeting RELA and TGFBR2, 
simultaneously (Keklikoglou et al., 2012).  
Diagnosis: analysis of circulating miR-373 in the 
plasma of breast cancer patients revealed that miR-
373 was upregulated in 35 patients with metastatic 
breast cancer to the lymph-nodes compared to 25 
patients with non-metastatic disease (Chen et al., 
2012). Furthermore, increased amounts of 
circulating miR-373 in the serum of breast cancer 
patients have been reported when compared to 
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healthy donors, however, no difference in 
circulating miR-373 amounts was observed 
between patients with metastatic and non-metastatic 
disease (Eichelser et al., 2013). 
Prostate cancer 
Oncogenesis 
miR-373 has been reported to be downregulated in 
5 matched prostate tumor specimens compared to 
benign tissue (Yang et al., 2009). However, 
overexpression of miR-373 or miR-520c markedly 
reduced CD44 total protein levels, while it 
stimulated prostate cancer cell invasion in vitro 
(Yang et al., 2009). On the contrary, Walter and 
colleagues analyzed 37 prostate cancer specimens 
that were manually microdissected to obtain cancer 
cells, adjacent stroma cells and normal epithelium, 
which were then analyzed by qRT-PCR using RT2-
PCR arrays for miRNA expression (Walter et al., 
2013). The profiling revealed that miR-372, a 
member of the miR-373 family, was upregulated in 
both tumor and stroma compartments compared to 
normal epithelium (Walter et al., 2013). In addition, 
the expression of miR-373 was found to be 
significantly upregulated in high grade tumors 
(Gleason score ≥8) compared to low grade tumors 
(Gleason score <6) (Walter et al., 2013). 
Childhood B-cell precursor acute 
lymphoblastic leukemia (pre-B-ALL) 
Oncogenesis 
miRNA expression profiling in blast cells revealed 
miR-373* to be downregulated in pre-B-ALL 
patients compared to their healthy counterparts (Ju 
et al., 2009). 
Esophageal cancer 
Oncogenesis 
miR-373 has an oncogenic role in esophageal 
cancer cell lines and tumors by targeting the tumor 
suppressor LATS2 and as such, promoting cell 
growth (Lee et al., 2009). This tumorigenic role 
was further confirmed by qRT-PCR which revealed 
that miR-373 was upregulated in 11 out of 23 
matched esophageal cancer tissues compared to 
their adjacent non-tumor counterparts (Lee et al., 
2009). 
Fibrosarcoma 
Oncogenesis 
miR-373 as well as miR-520c have been 
demonstrated to indirectly regulate MMP9 
expression in human fibrosarcoma HT1080 cells by 
directly targeting mTOR and SIRT1, two negative 
regulators of RAS/MEK/ERK and NF-kB 
signaling, respectively (Liu and Wilson, 2012). 
Thus, miR-373 promotes cell migration and growth 
by inducing both, ERK- and NF-kB-dependent 
MMP9 expression (Liu and Wilson, 2012). 
Gastric cancer 
Oncogenesis 
miR-373, as well as miR-520c-5p and miR-372 
were reported to be upregulated in gastric cancer 
cells compared to cancer stem cells (CSCs) which 
had been previously sorted as CD44+ cells from the 
same gastric cancer cell line MKN-45 (Golestaneh 
et al., 2012).  
Infection of gastric epithelial cells with 
Helicobacter pylori, a pathogen that is associated 
with the development of atrophic gastritis and 
gastric carcinoma, has been shown to cause miR-
373 downregulation and as such cell cycle arrest of 
highly proliferating gastric epithelial cells through 
upregulation of LATS2, a miR-373 direct target 
(Belair et al., 2011). 
Hepatocellular carcinoma (HCC) 
Oncogenesis 
miR-373 has been found to be upregulated in 26 
HCC tissues compared with their matched normal 
adjacent counterparts, as analyzed by qRT-PCR 
(Wu et al., 2011). Moreover, miR-373 was shown 
to promote cell cycle progression from G1 to S 
phase and cell proliferation in HCC cell lines by 
targeting protein phosphatase 6 (PPP6C) (Wu et al., 
2011). In agreement with this study, Toffanin and 
colleagues reported that miRNAs from the C19MC 
cluster were upregulated in a panel of 89 HCC 
patients, as determined by miRNA microarray 
profiling (Toffanin et al., 2011). In particular, miR-
517a and miR-520c were associated with increased 
cell proliferation and tumor growth, using in vitro 
and in vivo approaches (Toffanin et al., 2011). 
Interestingly, miRNA microarray analysis revealed 
that miR-373 was upregulated in the HCC cells, 
HepG2, upon cell infection with the hepatitis B 
virus (HBV), a pathogen that is frequently 
associated with liver diseases, including 
inflammation, cirrhosis and cancer (Guo et al., 
2011). In addition, miR-373 was shown to regulate 
the expression of the virus in the host cells by 
directly regulating NFIB expression (Guo et al., 
2011). Nevertheless, it should be noted that other 
members of the miR-373 family that share identical 
seed sequence were found to be downregulated in 
HCC (Zhang et al., 2012a; Zhang et al., 2012b). For 
instance, the promoter of miR-520e has been shown 
to be hypermethylated in HCC tissues and cell 
lines, thus leading to abrogated miR-520e 
expression (Zhang et al., 2012a). In addition, miR-
520b and miR-520e have been shown to inhibit 
tumor growth in HCC using xenograft mouse 
models, by targeting MEKK2, CCND1 and NIK, 
respectively (Zhang et al., 2012a; Zhang et al., 
2012b). 
Lung cancer 
Oncogenesis 
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Overexpression of miR-373 in A549 lung cancer 
cells inhibited cell migration by increasing E-
cadherin expression levels (Wu et al., 2012). Place 
and colleagues had previously reported that miR-
373 may enhance E-cadherin expression at the 
transcriptional level by targeting its promoter 
sequence in PC-3 cells (Place et al., 2008). 
Ovarian cancer 
Oncogenesis 
miR-373 as well as miR-372 were identified as 
inducers of cell proliferation in human epithelial 
ovary cancer cells, A2780, using a gain-of-function 
miRNA screen to identify miRNA regulators of 
ovarian cancer cell viability (Nakano et al., 2013). 
Testicular germ cell tumors (TGCTs) 
Oncogenesis 
miR-373 was initially identified as an oncogene in 
testicular germ cell tumorigenesis. In particular, 
ectopic expression of miR-373 in primary 
fibroblasts (BJ/ET) which were subsequently 
transduced with oncogenic RAS (RASV12), 
inhibited RAS-induced senescence and enhanced 
cellular transformation along with the RAS 
oncogene, in the presence of wild-type p53 
(Voorhoeve et al., 2006). Furthermore, miR-373 
expression was detected in 4 out of 7 cell lines 
tested which were derived from nonseminomatous 
tumors, while miR-373-371 cluster was barely 
expressed in other somatic cancer cell lines tested 
originating from breast, lung and brain tumors, as 
determined by an RNase protection assay (RPA) 
(Voorhoeve et al., 2006). In a panel of primary 
seminomas, nonseminomas, and spermatocytic 
seminomas analyzed for miR-372 expression, this 
cluster was found to be upregulated in most 
seminomas (28/32) and nonseminomas (14/21), 
while no miR-372 expression was detected in 
neither spermatocytic-seminoma tumors nor in 
normal testis tissues. Of note, tumors with high 
miR-372-373 expression did not contain mutated 
p53 alleles (Voorhoeve et al., 2006). Last but not 
least, miR-372 and mir-373 were found to 
neutralize p53-mediated CDK inhibition, partially 
by directly targeting LATS2 tumor suppressor 
(Voorhoeve et al., 2006).  
In another study, miR-373 and miR-372 expression 
was strongly upregulated in 11 seminoma tissues 
compared to 11 normal testicular tissues, as 
determined by miRNA microarray analysis (Bing et 
al., 2012). 
Pancreatic cancer 
Oncogenesis 
The zinc importer ZIP4 has been recently shown to 
transcriptionally regulate miR-373 expression in 
pancreatic cancer through CREB activation and 
binding to the miR-373 promoter (Zhang et al., 
2013).  
In particular, pancreatic ductal adenocarcinoma 
cells (PDAC) MiaPaca-2 overexpressing ZIP4 were 
shown to also overexpress miR-373, as determined 
by miRNA microarray analysis. At the same time, 
dampening ZIP4 expression in AsPC-1 cells using a 
short hairpin RNA (shRNA) against ZIP4 resulted 
in downregulation of miR-373 expression 
compared to control cells (Zhang et al., 2013). Of 
note, ZIP4-dependent upregulation of miR-373 led 
to increased cell invasion, proliferation and 
accelerated tumor growth in vivo, using a xenograft 
mouse model of PDAC. The oncogenic function of 
miR-373 was shown to be mediated by direct 
targeting of CD44, LATS2 and TP53INP1 (Zhang 
et al., 2013). 
Hilar cholangiocarcinoma 
Prognosis 
Analysis of 48 patients with hilar 
cholangiocarcinoma revealed that decreased 
expression of miR-373 was associated with poor 
cell differentiation, advanced clinical stage and 
shorter overall and disease-free survival (Chen et 
al., 2011a). 
Oncogenesis 
The promoter miR-373 has been found to be 
methylated in hilar cholangiocarcinomas and as 
such, its expression levels are decreased in 
malignant tissues (Chen et al., 2011a). Methyl-
CpG-binding domain protein 2 (MBD2) is a direct 
target of miR-373 in hilar cholangiocarcinoma 
(Chen et al., 2011b). 
Colon cancer 
Oncogenesis 
Using a microarray-based trasncriptomic approach, 
miR-373 was identified to be epigenetically 
regulated in the colon cancer cell line DLD-1 which 
was treated with 5'-aza'2'-deoxycytidine (DAC), as 
its expression levels were increased upon treatment 
compared to control cells (Tanaka et al., 2011). The 
epigenetic regulation of miR-373 was further 
confirmed by bisulfite sequencing analysis which 
revealed aberrant methylation of the miR-373 
promoter in colon cancer cells. 40 colon cancer 
specimens were analyzed for miR-373 expression 
levels (Tanaka et al., 2011). In line with the 
aforementioned observations, miR-373 was 
downregulated in colon cancer specimens compared 
to their normal counterparts, while aberrant 
methylation of miR-373 promoter was identified in 
87,5% of the colon cancer specimens using 
methylation-specific PCR (Tanaka et al., 2011). 
The oncogene RAB22A has been identified as a 
direct target of miR-373 in colon cancer (Tanaka et 
al., 2011). 
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